UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

RA-4: 13-cis Retinoic Acid for Treatment of Men With Azoospermia

Phase 2

Completed

Conditions: Male Infertility, Azoospermia

Interventions: Drug: 13-cis retinoic acid

First Posted Date: 2017-10-27

Last Posted Date: 2021-10-26

Lead Sponsor: University of Washington

Target Recruit Count: 10

Registration Number: NCT03323801

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

Cerebral Monitor Guided Therapy on Cerebral Outcomes After Cardiac Surgery

Not Applicable

Not yet recruiting

Conditions: Cardiac Surgery
Cerebral Function
Protein Metabolomics
Cardiopulmonary Bypass

Interventions: Other: Perioperative and postoperative management

First Posted Date: 2017-10-20

Last Posted Date: 2021-02-23

Lead Sponsor: University of Washington

Target Recruit Count: 20

Registration Number: NCT03316183

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

Functional Restoration and Integrative Therapies in Service Members With Neuromusculoskeletal Injury

Not Applicable

Active, not recruiting

Conditions: Chronic Pain

Interventions: Behavioral: Standard Rehabilitative Care
Behavioral: Complementary and Integrative Therapies

First Posted Date: 2017-09-29

Last Posted Date: 2022-10-12

Lead Sponsor: University of Washington

Target Recruit Count: 280

Registration Number: NCT03297905

Locations: 🇺🇸
Madigan Army Medical Center, Tacoma, Washington, United States

NRC:Improving Healthcare for Cognitively Impaired Elders and Their Caregivers

Not Applicable

Conditions: Nurse Training
Alzheimer Disease

Interventions: Behavioral: RDAD Training

First Posted Date: 2017-09-21

Last Posted Date: 2018-05-15

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT03289377

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Microgrid II - Electrocorticography Signals for Human Hand Prosthetics

Recruiting

Conditions: Epilepsy Intractable

First Posted Date: 2017-09-21

Last Posted Date: 2021-04-27

Lead Sponsor: University of Washington

Target Recruit Count: 20

Registration Number: NCT03289572

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States

Mandibular Overdenture Clinical Trial Comparing Parallel Sided and Tapered Dental Implants

Not Applicable

Completed

Conditions: Dental Implants

Interventions: Device: Nobel Biocare titanium dental implants

First Posted Date: 2017-09-06

Last Posted Date: 2024-01-09

Lead Sponsor: University of Washington

Target Recruit Count: 48

Registration Number: NCT03272828

Locations: 🇺🇸
the Regional Research Clinic, School of Dentistry at the University of Washington, Seattle, Washington, United States

Adjuvant Avelumab in Merkel Cell Cancer

Phase 3

Active, not recruiting

Conditions: Stage III Merkel Cell Carcinoma AJCC v8
Stage IIIB Merkel Cell Carcinoma AJCC v8
Stage IIIA Merkel Cell Carcinoma AJCC v8

Interventions: Drug: Avelumab
Other: Peripheral Blood Collection
Other: Placebo

First Posted Date: 2017-09-05

Last Posted Date: 2025-03-19

Lead Sponsor: University of Washington

Target Recruit Count: 101

Registration Number: NCT03271372

Locations: 🇺🇸
University of California Irvine Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
University of Colorado Cancer Center University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

and more 6 locations

Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

Phase 2

Terminated

Conditions: Marginal Zone Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Waldenstrom Macroglobulinemia
Refractory Marginal Zone Lymphoma
Refractory Waldenstrom Macroglobulinemia
Waldenstrom Macroglobulinemia

Interventions: Drug: Carfilzomib
Other: Laboratory Biomarker Analysis
Biological: Rituximab

First Posted Date: 2017-08-31

Last Posted Date: 2020-01-18

Lead Sponsor: University of Washington

Target Recruit Count: 4

Registration Number: NCT03269552

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Phase 1

Terminated

Conditions: Stage IV Renal Cell Cancer
Stage III Renal Cell Cancer
Metastatic Clear Cell Renal Cell Carcinoma
Advanced Clear Cell Renal Cell Carcinoma

Interventions: Biological: Aldesleukin
Biological: Pembrolizumab

First Posted Date: 2017-08-24

Last Posted Date: 2023-08-21

Lead Sponsor: University of Washington

Target Recruit Count: 6

Registration Number: NCT03260504

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Refractory Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma

Interventions: Drug: Carfilzomib
Other: Chemosensitivity Assay
Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Drug: Panobinostat

First Posted Date: 2017-08-21

Last Posted Date: 2022-05-09

Lead Sponsor: University of Washington

Target Recruit Count: 9

Registration Number: NCT03256045

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy